These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17223657)

  • 21. Safety of treatments for primary Sjögren's syndrome.
    van Nimwegen JF; Moerman RV; Sillevis Smitt N; Brouwer E; Bootsma H; Vissink A
    Expert Opin Drug Saf; 2016; 15(4):513-24. PubMed ID: 26809028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
    Dörner T; Posch MG; Li Y; Petricoul O; Cabanski M; Milojevic JM; Kamphausen E; Valentin MA; Simonett C; Mooney L; Hüser A; Gram H; Wagner FD; Oliver SJ
    Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren's Syndrome: A Randomized Clinical Trial.
    Posada J; Valadkhan S; Burge D; Davies K; Tarn J; Casement J; Jobling K; Gallagher P; Wilson D; Barone F; Fisher BA; Ng WF
    Arthritis Rheumatol; 2021 Jan; 73(1):143-150. PubMed ID: 32798283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.
    Sankar V; Brennan MT; Kok MR; Leakan RA; Smith JA; Manny J; Baum BJ; Pillemer SR
    Arthritis Rheum; 2004 Jul; 50(7):2240-5. PubMed ID: 15248223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viral antigens elicit augmented immune responses in primary Sjögren's syndrome.
    Björk A; Thorlacius GE; Mofors J; Richardsdotter Andersson E; Ivanchenko M; Tingström J; James T; Brokstad KA; Cox RJ; Jonsson R; Kvarnström M; Wahren-Herlenius M
    Rheumatology (Oxford); 2020 Jul; 59(7):1651-1661. PubMed ID: 31665501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum immunoglobulin G4 in Sjögren's syndrome: a pilot study.
    Maślińska M; Wojciechowska B; Mańczak M; Kwiatkowska B
    Rheumatol Int; 2020 Apr; 40(4):555-561. PubMed ID: 32062697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of biological DMARDs modulating B cells in primary Sjögren's syndrome: Systematic review and meta-analysis.
    Letaief H; Lukas C; Barnetche T; Gaujoux-Viala C; Combe B; Morel J
    Joint Bone Spine; 2018 Jan; 85(1):15-22. PubMed ID: 28673789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue.
    Haacke EA; van der Vegt B; Meiners PM; Vissink A; Spijkervet FK; Bootsma H; Kroese FG
    Clin Exp Rheumatol; 2017; 35(2):317-320. PubMed ID: 27908305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
    Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
    Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stratifying primary Sjögren's syndrome: killers in the balance?
    Bowman SJ; Fisher BA
    Arthritis Res Ther; 2015 Dec; 17():351. PubMed ID: 26639390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sjögren's syndrome: current therapies remain inadequate for a common disease.
    Fox RI
    Expert Opin Investig Drugs; 2000 Sep; 9(9):2007-16. PubMed ID: 11060789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus.
    Tam LS; Li EK; Wong CK; Lam CW; Szeto CC
    Lupus; 2004; 13(8):601-4. PubMed ID: 15462490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physical fatigue characterises patient experience of primary Sjögren's syndrome.
    Arends S; Meiners PM; Moerman RV; Kroese FG; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Clin Exp Rheumatol; 2017; 35(2):255-261. PubMed ID: 28032845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
    Gottenberg JE; Dörner T; Bootsma H; Devauchelle-Pensec V; Bowman SJ; Mariette X; Bartz H; Oortgiesen M; Shock A; Koetse W; Galateanu C; Bongardt S; Wegener WA; Goldenberg DM; Meno-Tetang G; Kosutic G; Gordon C
    Arthritis Rheumatol; 2018 May; 70(5):763-773. PubMed ID: 29381843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of CD5 and CD23 on B cells of patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren's syndrome. Relationship with disease activity and treatment.
    Ebo D; DeClerck LS; Bridts CH; Stevens WJ
    In Vivo; 1994; 8(4):577-80. PubMed ID: 7534494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
    Meijer JM; Meiners PM; Vissink A; Spijkervet FK; Abdulahad W; Kamminga N; Brouwer E; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2010 Apr; 62(4):960-8. PubMed ID: 20131246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial.
    van der Heijden EHM; Blokland SLM; Hillen MR; Lopes APP; van Vliet-Moret FM; Rosenberg AJWP; Janssen NG; Welsing PMJ; Iannizzotto V; Tao W; Pandit A; Barone F; Kruize AA; Radstake TRDJ; van Roon JAG
    Lancet Rheumatol; 2020 May; 2(5):e260-e269. PubMed ID: 38273473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sjögren's syndrome - not just Sicca: renal involvement in Sjögren's syndrome.
    Kaufman I; Schwartz D; Caspi D; Paran D
    Scand J Rheumatol; 2008; 37(3):213-8. PubMed ID: 18465457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary Sjogren's syndrome: current and prospective therapies.
    Thanou-Stavraki A; James JA
    Semin Arthritis Rheum; 2008 Apr; 37(5):273-92. PubMed ID: 17714766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infliximab in patients with primary Sjögren's syndrome: a pilot study.
    Steinfeld SD; Demols P; Salmon I; Kiss R; Appelboom T
    Arthritis Rheum; 2001 Oct; 44(10):2371-5. PubMed ID: 11665979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.